
Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Caribou Biosciences in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will earn ($2.17) per share for the year. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share.
Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.43). The business had revenue of $2.35 million for the quarter, compared to analyst estimates of $1.48 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.
Several other analysts also recently commented on CRBU. Wall Street Zen downgraded Caribou Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target (down from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.50.
Get Our Latest Stock Analysis on Caribou Biosciences
Caribou Biosciences Stock Down 4.3%
NASDAQ:CRBU traded down $0.05 on Wednesday, hitting $1.11. The stock had a trading volume of 1,162,421 shares, compared to its average volume of 1,358,770. The business's fifty day moving average is $0.93 and its 200 day moving average is $1.26. The company has a market cap of $103.24 million, a PE ratio of -0.67 and a beta of 2.44. Caribou Biosciences has a 52 week low of $0.66 and a 52 week high of $3.00.
Institutional Trading of Caribou Biosciences
Several large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in shares of Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock worth $3,969,000 after purchasing an additional 2,062,563 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its position in Caribou Biosciences by 28.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock valued at $3,360,000 after acquiring an additional 467,738 shares in the last quarter. Two Sigma Advisers LP lifted its position in Caribou Biosciences by 39.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company's stock valued at $2,338,000 after acquiring an additional 416,600 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in Caribou Biosciences by 19.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,442,121 shares of the company's stock valued at $1,317,000 after acquiring an additional 234,052 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in Caribou Biosciences by 23.7% in the 4th quarter. Two Sigma Investments LP now owns 1,118,696 shares of the company's stock valued at $1,779,000 after acquiring an additional 214,239 shares in the last quarter. 77.51% of the stock is owned by institutional investors.
About Caribou Biosciences
(
Get Free Report)
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
See Also

Before you consider Caribou Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caribou Biosciences wasn't on the list.
While Caribou Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.